Merck & Co., Inc. $MRK Stock Position Cut by Canandaigua National Bank & Trust Co.

Canandaigua National Bank & Trust Co. lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 16.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 70,117 shares of the company’s stock after selling 13,736 shares during the quarter. Merck & Co., Inc. comprises about 0.9% of Canandaigua National Bank & Trust Co.’s holdings, making the stock its 23rd biggest holding. Canandaigua National Bank & Trust Co.’s holdings in Merck & Co., Inc. were worth $10,189,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Abound Financial LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Bullseye Investment Management LLC purchased a new position in Merck & Co., Inc. in the 2nd quarter valued at approximately $27,000. Horizons Wealth Management acquired a new position in shares of Merck & Co., Inc. in the third quarter worth $30,000. Graney & King LLC grew its stake in shares of Merck & Co., Inc. by 400.0% in the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares in the last quarter. Finally, Montgomery Financial Services LLC purchased a new stake in shares of Merck & Co., Inc. during the second quarter worth $41,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Up 0.5%

NYSE:MRK traded up $0.72 during trading hours on Wednesday, hitting $142.66. The company’s stock had a trading volume of 6,349,422 shares, compared to its average volume of 10,674,509. Merck & Co., Inc. has a 52-week low of $82.01 and a 52-week high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The stock has a market capitalization of $351.96 billion, a P/E ratio of 114.12, a price-to-earnings-growth ratio of 6.08 and a beta of 0.21. The stock has a fifty day moving average of $143.10 and a 200-day moving average of $127.76.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.Merck & Co., Inc.’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year, the business earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.4%. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Insider Transactions at Merck & Co., Inc.

In related news, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the transaction, the executive vice president directly owned 46,613 shares of the company’s stock, valued at $6,106,303. This represents a 24.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Richard Deluca sold 20,784 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the sale, the executive vice president directly owned 134,703 shares in the company, valued at approximately $17,569,312.29. The trade was a 13.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 over the last three months. 0.17% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on MRK. Cantor Fitzgerald reiterated a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a report on Monday, July 6th. Guggenheim increased their price target on Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. Rothschild & Co Redburn lifted their price objective on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, July 6th. HSBC boosted their price objective on Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Jefferies Financial Group upped their target price on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $148.80.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Morgan Stanley maintained an “overweight” rating on Merck while trimming its price target from $179 to $177, still implying substantial upside. The rating reflects confidence in Keytruda, Merck’s broader product portfolio and its longer-term outlook. Morgan Stanley price target update
• Positive Sentiment: Recent commentary argues that Merck’s pullback over the past month may represent a buying opportunity. Keytruda remains the primary growth driver, while newer products and pipeline assets could help support growth after 2028. Merck stock valuation and outlook
• Neutral Sentiment: Sell-side analysts collectively rate Merck & Co. (MRK) a “moderate buy,” indicating generally favorable sentiment but not unanimous conviction. Merck analyst rating
• Negative Sentiment: A Dutch court ruled for Halozyme Therapeutics in a patent dispute, barring Merck from selling subcutaneous Keytruda in eight European markets. The injunction threatens the rollout of a potentially more convenient version of Merck’s largest drug and could delay related revenue opportunities in Europe. Merck injectable Keytruda European injunction

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.